Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

GEVELOT S.A.: Number of Shares and Voting rights  4 January 2024
GEVELOT S.A.: Number of Shares and Voting rights 4 January 2024
GEVELOT S.A.: Number of Shares and Voting rights 4 January 2024
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D


ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant

Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

Kaufman & Broad SA: HALF-YEAR LIQUIDITY CONTRACT STATEMENT FOR KAUFMAN & BROAD SA _ 2023, decembre 31
Kaufman & Broad SA: HALF-YEAR LIQUIDITY CONTRACT STATEMENT FOR KAUFMAN & BROAD SA _ 2023, decembre 31
Kaufman & Broad SA: HALF-YEAR LIQUIDITY CONTRACT STATEMENT FOR KAUFMAN & BROAD SA _ 2023, decembre 31
EQS-News: Abivax 2024 Financial Communication Calendar
EQS-News: Abivax 2024 Financial Communication Calendar
EQS-News: Abivax 2024 Financial Communication Calendar
Poxel Announces its Financial Calendar for 2024: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces its Financial Calendar for 2024


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
ROCTOOL: Proposed entry of ENRX into the capital of ROCTOOL
ROCTOOL: Proposed entry of ENRX into the capital of ROCTOOL
ROCTOOL: Proposed entry of ENRX into the capital of ROCTOOL
Median Technologies Announces the Drawdown of €8.5m Corresponding to the Final Tranche of the European Investment Bank Loan: https://mms.businesswire.com/media/20200113005579/en/767035/5/Median_strapline.jpg
Median Technologies Announces the Drawdown of €8.5m Corresponding to the Final Tranche of the European Investment Bank Loan


Regulatory News:



Median Technologies (Paris:ALMDT) announces that it has received approval from the European Investment Bank to draw down the final tranche of the loan granted on December 18

Poxel Provides Corporate Update: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Provides Corporate Update


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Transgene Announces Upcoming Investor Meetings: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Announces Upcoming Investor Meetings


Regulatory News:



TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below.



Transgene will meet

Prodware: Prodware steps up its expansion in Europe with the acquisition of Nut Consulting in Spain
Prodware: Prodware steps up its expansion in Europe with the acquisition of Nut Consulting in Spain
Prodware: Prodware steps up its expansion in Europe with the acquisition of Nut Consulting in Spain
Sensorion Publishes Results of Combined General Meeting Resolutions: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Publishes Results of Combined General Meeting Resolutions


Regulatory News:



Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

FOCUS ENTERTAINMENT: Geoffroy Sardin's Appointment as Deputy CEO of Focus Entertainment
FOCUS ENTERTAINMENT: Geoffroy Sardin's Appointment as Deputy CEO of Focus Entertainment
FOCUS ENTERTAINMENT: Geoffroy Sardin's Appointment as Deputy CEO of Focus Entertainment
FOCUS ENTERTAINMENT: Creation of Scripteam and acquisition of stakes in two studios to build an audiovisual platform
FOCUS ENTERTAINMENT: Creation of Scripteam and acquisition of stakes in two studios to build an audiovisual platform
FOCUS ENTERTAINMENT: Creation of Scripteam and acquisition of stakes in two studios to build an audiovisual platform
Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO): https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)


Regulatory News:



Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Median Technologies and PASREL-Imagerie Join Forces to Deliver Smart Imaging Biomarkers Supporting the Development of New Oncology Drugs in Precision Medicine: https://mms.businesswire.com/media/20200113005579/en/767035/5/Median_strapline.jpg
Median Technologies and PASREL-Imagerie Join Forces to Deliver Smart Imaging Biomarkers Supporting the Development of New Oncology Drugs in Precision Medicine


Regulatory News:



Median Technologies (Paris:ALMDT) and PASREL-Imagerie, announce today the signing of an agreement to deliver cutting-edge imaging biomarkers for the development of new oncology

FOCUS ENTERTAINMENT: H1 2023/2024 results : strong growth in revenue and lower profitability
FOCUS ENTERTAINMENT: H1 2023/2024 results : strong growth in revenue and lower profitability
FOCUS ENTERTAINMENT: H1 2023/2024 results : strong growth in revenue and lower profitability
RALLYE S.A.: Appeal against the decision of the Sanctions Commission of the French Financial Market Authority
RALLYE S.A.: Appeal against the decision of the Sanctions Commission of the French Financial Market Authority
RALLYE S.A.: Appeal against the decision of the Sanctions Commission of the French Financial Market Authority
Eutelsat OneWeb signs multi-million dollar exclusive distribution agreement with Rawafed Libya to deliver connectivity services across Libya.: https://mms.businesswire.com/media/20191112005524/en/397236/5/Eutelsat_Communications_logo.jpg
Eutelsat OneWeb signs multi-million dollar exclusive distribution agreement with Rawafed Libya to deliver connectivity services across Libya.


Regulatory News:



Eutelsat Group (Paris:ETL) (LSE:ETL), the world’s first GEO-LEO satellite operator, has today announced the signing of an exclusive distribution partnership agreement between

Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

FOCUS ENTERTAINMENT: Announces, at the Game Awards, the release date of WARHAMMER 40,000: SPACE MARINE 2 on September 9th, 2024 - A new impactful trailer for Banishers : Ghosts of New Eden
FOCUS ENTERTAINMENT: Announces, at the Game Awards, the release date of WARHAMMER 40,000: SPACE MARINE 2 on September 9th, 2024 - A new impactful trailer for Banishers : Ghosts of New Eden
FOCUS ENTERTAINMENT: Announces, at the Game Awards, the release date of WARHAMMER 40,000: SPACE MARINE 2 on September 9th, 2024 - A new impactful trailer for Banishers : Ghosts of New Eden
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy


Regulatory News:



Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the